PCSK9 and breast carcinoma: Furthermore, in the clinical dataset, we observed elevated expression of PCSK9 in 83 TNBC patients than 200 non‐TNBC patients (Figure 2J).[33] Additionally, according to the TCGA dataset in the UALCAN platform, the average mRNA expression level of PCSK9 from 116 TNBC patients is significantly higher than 566 patients with a luminal type of breast cancer or 114 normal tissues from breast cancer patients (Figure S2B, Supporting Information).